LIPITOR

LOE Approaching

atorvastatin calcium

NDAORALTABLETPriority Review
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA…

Clinical Trials (5)

NCT01964326Phase 3Completed

Actual Use Trial of Atorvastatin Calcium 10 mg

Started Oct 2013
1,311 enrolled
Hypercholesterolemia
NCT01446679N/ACompleted

Special Drug Use-Results Survey of Lipitor Tablets

Started Sep 2010
24,050 enrolled
Hypercholesterolemia
NCT01078285N/ACompleted

Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor

Started Mar 2010
500 enrolled
Medication Non-Adherence
NCT00540293Phase 4Completed

Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study

Started Oct 2007
425 enrolled
Dyslipidemias
NCT00137462Phase 3Completed

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Started Nov 2004
900 enrolled
Hyperlipidemia